5 Biotech Stocks Poised for Breakouts
Novavax
One stock in the biotechnology and drugs complex that's trending within range of triggering a major breakout trade is Novavax (NVAX), whose product pipeline focuses on a variety of infectious diseases and whose vaccine candidates have completed clinical trials that target pandemic influenza, seasonal influenza and respiratory syncytial virus. This stock is off to a hot start in 2012, with shares up over 60% so far.
If you take a look at the chart for Novavax, you'll notice that this stock has been trading inside of a large range for the past two months, with shares bouncing between $1.80 on the downside and $2.24 on the upside. A high-volume move outside of the upper-end of that range will trigger a major breakout trade for shares of Novavax.
>>5 Big Stock Charts You've Got to See to Believe
Traders should now look for long-biased trades in NVAX once it manages to break out above some near-term overhead resistance levels at $2.15 to $2.24 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 1 million shares. If that breakout triggers soon, then NVAX will have a great chance of re-testing or possibly taking out its next major overhead resistance levels at $2.70 to $3 a share. Any high-volume move above $3 could put NVAX's 2011 high into play at $3.50. One could look to buy NVAX off any weakness to anticipate that breakout, and simply use a stop that sits near $1.85 to $1.80 a share. Or a better strategy might be to buy off strength once it starts to clear $2.15 to $2.24 with volume, and then simply use a stop that sits just under its 50-day moving average of $2.01 a share.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV